More Americans are using psilocybin—especially those with mental health conditions, study shows

(Press-News.org)  Use of psilocybin, the hallucinogenic chemical found in what is known as  “magic mushrooms,” has increased significantly nationwide since 2019, according to a new study led by researchers at the University of Colorado Anschutz Medical Campus and Rocky Mountain Poison and Drug Safety.

The study was published today in the Annals of Internal Medicine.

The researchers found that psilocybin use increased across all age groups, with the largest rise in young adults and older adults.

“We found that since 2019, the number of people using psilocybin has gone up sharply,” said Karilynn Rockhill, PhD, co-lead author of the study and researcher at the Colorado School of Public Health. “This seems to line up with when some U.S. states began to decriminalize or legalize it.”

Some of the most significant findings include:

Lifetime use among adults rose from 10% in 2019 (about 25 million people) to 12.1% in 2023 (over 31 million people). Past-year use increased by 44% among young adults (ages 18–29) and 188% among adults over 30. People with mental health conditions or chronic pain were more likely to report using psilocybin. Psilocybin-related poison center calls rose dramatically. 201% in adults, 317% in teens and 723% in children between 2019 and 2023. In 2023, more adults used psilocybin than drugs like cocaine, LSD, methamphetamine or illegal opioids. “What really surprised us was how quickly these numbers changed and how many people using psilocybin had conditions like depression, anxiety or chronic pain,” said Rockhill. “New laws or growing interest in its potential mental health benefits may be prompting people to seek psilocybin as a form of self-treatment.”

Psilocybin has been studied as a possible treatment for conditions like PTSD, depression and substance use disorders, though it is not yet approved by the US Food and Drug Administration (FDA).

“Public views on psilocybin are shifting. However, that means we also need to make sure people understand the risks, know how to use it safely if they choose to and that health care systems are prepared,” said Joshua Black, PhD, co-lead author and senior scientist at Rocky Mountain Poison and Drug Safety, a division of Denver Health.

The study also revealed a gap in how well current medical coding systems track psilocybin-related problems in emergency departments. While poison center calls have gone way up, very few cases are recorded in hospital ambulatory data.

“If hospitals and public health systems aren’t seeing the full picture, they can’t respond appropriately,” said Black. “Improved tracking tools and education are critical as more states consider regulating or legalizing psilocybin.”

The study utilized data from five major national surveys from 2014-2023. Data was used from the National Survey on Drug Use and Health (NSDUH), the Survey of Non-Medical Use of Prescription Drugs (NMURx), Monitoring the Future (MTF), the National Poison Data System (NPDS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS).

This was a collaborative project with the Substance Abuse and Mental Health Administration (SAMHSA), but the views expressed here are those of the authors and may not represent the positions of SAMHSA.

 

About the University of Colorado Anschutz Medical Campus

The University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado – which see more than two million adult and pediatric patient visits yearly. Innovative, interconnected and highly collaborative, the CU Anschutz Medical Campus delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by $910 million in annual research funding, including $757 million in sponsored awards and $153 million in philanthropic gifts. 

END